Andrew Einhorn

Andrew J.
Einhorn was the founder of ESP Pharma, Inc., founded in 2003, where the title held was Chief Financial Officer & Senior Vice President.
Mr. Einhorn was the founder of Esprit Pharma, Inc., founded in 2005, with the title Chief Financial Officer & Executive Vice President from 2009 to 2011.
Mr. Einhorn was the founder of Oceana Therapeutics, Inc., founded in 2008, holding the title Chief Financial Officer & Executive VP from 2008 to 2012.
Current jobs include Independent Director at Pelthos Therapeutics, Inc. starting in 2025, Chief Financial Officer at Osmotica Pharmaceutical Corp.
since 2017, and Venture Advisor at Israel Biotech Fund since 2015.
Former jobs include Managing Director at The PNC Financial Services Group, Inc., Managing Director at Credit Lyonnais from 2001 to 2003, Chief Financial Officer at MYOS RENS Technology, Inc. from 2012 to 2013, Chief Financial Officer at Edge Therapeutics, Inc. from 2014 to 2017, Vice President at Chase Securities, Inc., Vice President at BT Securities Co., Ltd., Chief Accounting Officer at Cognition Therapeutics, Inc. in 2023, Chief Financial & Accounting Officer at RVL Pharmaceuticals Plc from 2017 to 2022, and Chief Financial Officer at RELIEF THERAPEUTICS Holding SA. Education includes undergraduate studies at American University, graduate studies at Northwestern University, and undergraduate studies at Middlebury College.